Delcath Systems

Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. It develops and commercializes CHEMOSAT and Melphalan Hydrochloride for Injection, which is a proprietary product used with the Delcath Hepatic Delivery System. The company was founded in August 1988 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Delcath Systems secures $85M funding, advances FDA approval for HEPZATO

Delcath Systems showcased financial resilience with strategic financing, highlighted progress in regulatory milestones, and outlined plans for revenue generation and market expansion.

Delcath Systems reports revenue growth and secures financing for Hepzato

Delcath Systems' Q1 2023 performance reflects revenue growth, strategic financing, and increased cash reserves, positioning the company for future success.
While facing challenges in a competitive landscape and post-approval payment transitions, opportunities lie in market expansion, innovation, and strategic partnerships.
Overall, Delcath Systems shows strength in product development, financial stability, and market readiness, with potential for growth through strategic initiatives and market penetration.

Delcath Systems readies for HEPZATO KIT launch amid financial stability

Delcath Systems is financially stable with a strategic focus on commercial launch preparations
Challenges lie in transitioning patients and ensuring timely physician training for site readiness
Opportunities exist in expedited approvals, site expansions, and product adoption strategies

Delcath Systems reports progress in HEPZATO commercialization and funding

Delcath Systems made progress in commercializing HEPZATO for metastatic uveal melanoma in the U.S.
The company secured funding to support operations and reported a healthy cash position.
While facing challenges with low Q4 revenue and increased expenses, opportunities exist in expanding usage and revenue growth.
Overall, Delcath Systems is poised for growth with a focus on driving adoption of HEPZATO in key cancer centers.

Delcath Systems posts strong Q1 results, eyes market expansion

Delcath Systems demonstrated solid financial performance in Q1 2024, with revenue growth and efficient cost management, positioning the company for future success.
While facing challenges in cost control and operational scaling, Delcath's strategic focus on partnerships, revenue-driven R&D, and market expansion presents growth opportunities.
Overall, Delcath's strong financial position, positive study results, and growth projections indicate a promising outlook for the company in the oncology market.

Delcath Systems reports strong Q2 revenue growth and expansion plans

Delcath Systems demonstrated robust financial performance in Q2 2024, driven by strong revenue from HEPZATO and CHEMOSAT, with a focus on expanding treatment sites and revenue targets.
Despite facing challenges in scaling operations and achieving revenue goals, the company's strategic strengths in sales, margins, and cash position position it well for future growth.
Opportunities lie in clinical trials, product expansion, and market penetration, offering avenues for sustained revenue growth and market leadership in the long term.

Delcath Systems reports robust revenue growth and eyes oncology market

Delcath Systems demonstrated solid revenue growth driven by HEPZATO and CHEMOSAT sales, with a focus on expanding treatment centers and advancing clinical trials.
While facing financial challenges and operational complexities, the company is poised for growth through new indications and market adoption strategies.
Engagement with medical professionals and strategic trial planning offer avenues for revenue expansion and market leadership in targeted oncology treatments.
Balancing financial sustainability with growth ambitions will be crucial for Delcath's success in navigating the competitive healthcare landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded in August 1988 and is headquartered in Queensbury, NY.

Delcath Systems (DCTH) CEO, Gerard Mitchell on Q3 2021 Results - Earnings Call Transcript

Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of -3.30% and -9.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Delcath Systems, Inc. (DCTH) Reports Q3 Loss, Misses Revenue Estimates

Delcath Systems (NASDAQ:DCTH) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

Recap: Delcath Systems Q3 Earnings

NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended September 30, 2021.

Delcath Systems Announces Third Quarter 2021 Results

Delcath Systems, Inc. (DCTH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Delcath Systems, Inc. (DCTH) Stock Jumps 6.6%: Will It Continue to Soar?

NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will participate in an upcoming virtual investor conference:

Delcath Systems to Participate in the Canaccord Virtual MedTech, Diagnostics and Digital Health & Services Forum on November 18, 2021

NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a comprehensive Investor Update event on Thursday, December 2nd, from 10:00am ET – 1:00pm ET.

Delcath Systems to Hold Investor Update on Focus Trial Data and Future Development Plans on December 2, 2021

Delcath Systems, Inc. (DCTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Delcath Systems, Inc. (DCTH) Report Negative Earnings Next Week? What You Should Know

NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on Nov 9, 2021 at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2021.

Delcath Systems Schedules Conference Call to Report 2021 Third Quarter Financial Results

Delcath Systems, Inc. (DCTH) CEO Gerard Michel on Q2 2021 Results - Earnings Call Transcript

Shares of Delcath Systems (NASDAQ:DCTH) fell 13.6% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 49.47% over the past year to ($0.96), which beat the estimate of ($0.99).

Delcath Systems: Q2 Earnings Insights

NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today reported business highlights and financial results for the second quarter ended June 30, 2021.

Delcath Systems Announces Second Quarter 2021 Results

NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that it has entered into a debt facility with Avenue Venture Opportunities Fund, L.P. ("Avenue Venture Fund") providing up to $20 million with an initial $15 million funded at close. Additional details concerning the debt facility will be contained in the company's Current Report on Form 8-K to be filed shortly with the Securities and Exchange Commission.

Delcath Systems Secures Up to a $20.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P.

NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on August 10, 2021 at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2021.

Delcath Systems Schedules Conference Call to Report 2021 Second Quarter Financial Results

NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that the company will present at Access to Giving Virtual Conference. The presentation will be given by Delcath's Chief Executive Officer, Gerard Michel. The conference is free to all registrants.

Delcath Systems to Present at Access to Giving Virtual Conference on July 13, 2021 at 3 p.m. ET

Delcath Systems is moving closer to submitting their NDA for their drug/device kit of melphalan hydrochloride with hepatic delivery system, HEPZATO. If approved, Delcath would have several. HEPZATO has produced some impressive data that shows it outperforming most of the contemporary therapies in metastatic ocular melanoma.

Delcath Systems: Ready To Return To A Previous Winner

NEW YORK, June 08, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution effect after the US market opens on June 28, according to a preliminary list of additions posted June 4.

Delcath Systems Set to Join Russell Microcap® Index

Delcath Systems Inc (NASDAQ: DCTH) has announced positive preliminary efficacy results from its FOCUS Phase 3 trial evaluating Hepzato Kit (melphalan hydrochloride for injection/hepatic delivery system) in patients with liver dominant metastatic ocular melanoma. Data were presented at the American Society of Clinical Oncology Annual Meeting.

Delcath Systems' Hepzato Achieves 44% Best Overall Response Compared to Best Alternative Care in Eye Cancer

As Previously Disclosed, the Prespecified Primary Endpoint, Objective Response Rate, Has Been Met by Exceeding the 95% CI Lower Bound Threshold for Success

Positive Preliminary Results from Delcath Systems' FOCUS Trial Presented at the 2021 ASCO Annual Meeting

NEW YORK, June 03, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced that management will present at:

Delcath Systems to Present at LD Micro Virtual Investor Conference on June 10, 2021, at 2:30pm ET

NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq:  DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will present at:

Delcath Systems to Present at Jefferies Virtual Healthcare Conference

Delcath Systems (DCTH) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Moving Average Crossover Alert: Delcath Systems (DCTH)

Delcath Systems, Inc. (DCTH) CEO Gerard Michel on Q1 2021 Results - Earnings Call Transcript

Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of -16.85% and 3.47%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Tops Revenue Estimates

Shares of Delcath Systems (NASDAQ:DCTH) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share rose 99.04% over the past year to ($1.04), which missed the estimate of ($0.98).

News for Delcath Systems Stock (DCTH)